Last 29 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -65.66 | — | — | 30.15 | — | 582.21 | — | 76.39 | — | 45.78 | — | — | — | 354.51 | — | — | — | 97.79 | — | — | — |
| — | — | — | -60.5% | — | +1171.8% | — | — | — | -87.1% | — | — | — | +262.5% | — | — | — | — | — | — | — | |
| P/S Ratio | 3.92 | 3.82 | 3.49 | 3.74 | 5.64 | 4.41 | 4.03 | 4.10 | 4.39 | 5.12 | 5.62 | 11.50 | 14.91 | 13.12 | 15.47 | 13.47 | 13.62 | 12.46 | 10.21 | 14.59 | 56.95 |
| — | -13.5% | -13.3% | -8.9% | +28.6% | -13.8% | -28.3% | -64.3% | -70.6% | -61.0% | -63.7% | -14.7% | +9.4% | +5.3% | +51.6% | -7.7% | -76.1% | -81.8% | -86.3% | -70.5% | — | |
| P/B Ratio | 4.09 | 3.72 | 3.86 | 4.05 | 4.59 | 4.62 | 4.06 | 4.07 | 4.09 | 4.35 | 4.72 | 9.02 | 11.44 | 9.64 | 10.49 | 8.69 | 7.86 | 8.19 | 9.96 | 6.10 | 6.46 |
| — | -19.4% | -5.1% | -0.5% | +12.2% | +6.1% | -13.9% | -54.8% | -64.3% | -54.9% | -55.0% | +3.8% | +45.6% | +17.7% | +5.4% | +42.5% | +21.6% | +1.9% | +78.7% | +26.4% | — | |
| P/FCF | — | 9.98 | — | — | — | — | 15.44 | 2812.68 | — | 20.25 | 18.31 | — | — | 97.55 | — | 97.68 | 97.21 | 78.40 | — | — | — |
| — | — | — | — | — | — | -15.7% | — | — | -79.2% | — | — | — | +24.4% | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 47.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 153.89 | 25.33 | — | 132.10 | — | 41.13 | — | 40.20 | — | — | — | — | — | — | — | 67.28 | — | — | — |
| — | — | — | -38.4% | — | +228.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 99.3% | 99.1% | 99.6% | 96.6% | 99.5% | 98.9% | 99.1% | 99.6% | 99.4% | 97.7% | 99.7% | 99.7% | 96.9% | 99.4% | 99.6% | 52.9% | 96.3% | 94.8% | 98.9% | -204.4% |
| — | -0.2% | +0.1% | +0.5% | -3.0% | +0.1% | +1.2% | -0.5% | -0.1% | +2.6% | -1.7% | +0.0% | +88.6% | +0.7% | +4.9% | +0.7% | +125.9% | +152.4% | -5.2% | -1.1% | +77.1% | |
| Operating Margin | -11.3% | -13.3% | -2.6% | 6.8% | -18.8% | -6.9% | -15.2% | -3.9% | -23.1% | -10.6% | -21.2% | -37.6% | -24.3% | -19.4% | -23.0% | -26.9% | -52.3% | -21.9% | -21.9% | -73.2% | -573.8% |
| — | -92.5% | +83.0% | +277.2% | +18.6% | +34.7% | +28.5% | +89.7% | +4.8% | +45.4% | +7.7% | -39.7% | +53.5% | +11.2% | -5.4% | +63.3% | +90.9% | +95.8% | +96.4% | +81.0% | -111.2% | |
| Net Margin | -8.9% | -13.9% | -0.7% | 12.2% | -28.8% | 0.8% | -10.5% | 5.4% | -28.3% | 10.9% | -15.4% | -34.7% | -28.1% | 3.7% | -28.5% | -35.6% | -56.3% | 15.1% | -19.1% | -71.8% | -597.4% |
| — | -1937.9% | +93.4% | +127.3% | -1.7% | -93.0% | +31.8% | +115.4% | -0.6% | +194.4% | +45.9% | +2.6% | +50.0% | -75.5% | -48.9% | +50.4% | +90.6% | +103.0% | +96.7% | +79.6% | -134.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.1% | -3.4% | -0.2% | 3.3% | -5.7% | 0.2% | -2.7% | 1.4% | -6.4% | 2.4% | -3.2% | -7.5% | -5.4% | 0.7% | -4.9% | -5.1% | -8.7% | 3.2% | -4.0% | -7.2% | -18.1% |
| — | -1794.1% | +92.6% | +146.4% | +11.0% | -91.6% | +16.9% | +118.1% | -19.2% | +241.0% | +33.5% | -46.2% | +37.8% | -78.2% | -20.2% | +28.8% | +52.2% | +126.9% | +60.4% | +51.0% | +65.9% | |
| ROA | -2.5% | -1.3% | -0.1% | 1.2% | -2.1% | 0.1% | -1.0% | 0.5% | -2.3% | 0.8% | -1.2% | -3.3% | -3.4% | 0.4% | -3.1% | -3.3% | -5.7% | 2.0% | -2.3% | -4.1% | -10.7% |
| — | -1859.2% | +92.4% | +145.9% | +9.5% | -91.3% | +15.2% | +114.8% | +32.5% | +89.6% | +62.6% | -1.4% | +40.6% | -77.9% | -33.7% | +20.5% | +46.9% | +126.9% | +64.6% | +48.5% | +7.5% | |
| ROIC | -7.4% | -6.4% | -0.6% | 1.5% | -3.2% | -1.6% | -3.3% | -0.8% | -4.4% | -2.0% | -7.4% | -474.7% | -296.1% | -11049.0% | -236.2% | -78.7% | -96.8% | -34.6% | -24.6% | -95.8% | -856.3% |
| — | -300.1% | +81.9% | +286.6% | +27.7% | +18.5% | +54.9% | +99.8% | +98.5% | +100.0% | +96.9% | -503.0% | -205.9% | -31876.8% | -859.3% | +17.8% | +88.7% | +85.9% | +98.0% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.15 | 0.10 | 1.04 | 1.11 | 1.15 | 1.10 | 1.12 | 1.15 | 1.20 | 1.27 | 1.32 | 1.31 | 0.23 | 0.24 | 0.24 | 0.25 | 0.24 | 0.25 | 0.41 | 0.40 | 0.37 |
| — | -91.1% | -7.8% | -3.5% | -4.5% | -13.7% | -14.7% | -12.8% | +420.5% | +427.1% | +443.5% | +429.0% | -4.1% | -3.9% | -41.1% | -37.3% | -35.4% | -21.6% | +44.5% | +52.7% | -72.3% | |
| Debt / EBITDA | — | — | — | 52.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.04 | 4.62 | 4.47 | 4.18 | 4.04 | 6.00 | 5.89 | 6.36 | 4.38 | 3.78 | 5.17 | 5.96 | 3.80 | 4.26 | 4.28 | 4.56 | 4.70 | 5.23 | 3.98 | 4.58 | 4.29 |
| — | -23.1% | -24.2% | -34.3% | -7.8% | +58.9% | +14.0% | +6.6% | +15.2% | -11.3% | +20.8% | +30.8% | -19.1% | -18.5% | +7.5% | -0.5% | +9.5% | -0.3% | -30.1% | -26.5% | +54.4% | |
| Quick Ratio | 4.01 | 4.59 | 4.44 | 4.15 | 4.01 | 5.97 | 5.86 | 6.31 | 4.36 | 3.76 | 5.15 | 5.94 | 3.77 | 4.24 | 4.26 | 4.55 | 4.69 | 5.21 | 3.97 | 4.57 | 4.29 |
| — | -23.2% | -24.3% | -34.3% | -7.9% | +58.8% | +13.8% | +6.4% | +15.5% | -11.3% | +20.9% | +30.5% | -19.6% | -18.7% | +7.2% | -0.5% | +9.3% | -0.5% | -30.2% | -26.6% | +48.1% | |
| Interest Coverage | -0.17 | -4.45 | 0.83 | 6.75 | -2.83 | 1.10 | -2.33 | 3.01 | -2.36 | 2.61 | -1.69 | -6.43 | -18.75 | -9.58 | -12.20 | -14.32 | -14.97 | 4.46 | -6.17 | -12.34 | -20.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMCR stock.
Immunocore Holdings plc's current P/E is -65.7x. The average P/E over the last 1 quarters is 30.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Immunocore Holdings plc's current operating margin is -11.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Immunocore Holdings plc's business trajectory between earnings reports.